overwhelms its primary enzymatic defenses, superoxide dismutases (SOD), elevated levels of pro-inflammatory cytokines, chemotactic factors, and adhesion molecules ensue, and nitric oxide is depleted with concomitant peroxynitrite formation. 2b Low SOD levels are associated with oxidative stress, 2 and there is considerable interest in developing therapeutics that mimic SOD. Cobalamins (Cbl, vitamin B 12 derivatives) are essential cobaltcontaining cofactors for two mammalian enzymes. 4a Cbl deficiency is common in the elderly (10-40%), 5 and Cbl supplementation can be beneficial in several inflammatory diseases including sepsis, arthritis, Alzheimer's disease, multiple sclerosis, and chronic fatigue syndrome. There is evidence that Cbl protects against oxidative stress associated pathologies. 4 Cbl modulates the immune response and influences cytokine and growth factor production. 4a,6 Cbl therapy normalizes levels of TNF-R (which inhibits SOD 7 ) and epidermal growth factor in Cbl deficient patients. 6 Cbl also suppresses production of inducible transcription factor NF-κB. 6 The exact mechanism(s) by which Cbl achieves these effects is unclear and difficult to ascribe solely to its known coenzyme activities. 4b We recently showed that Cbl protects against oxidative stress in a cellular model. 4e Given that an important intracellular Cbl form cob(II)alamin (Cbl(II)) 8 reacts rapidly with the radical nitric oxide (
) and that O 2 •-reacts rapidly with other Co(II) macrocycles, 10 Figure  S1 ). Catalase (1000 U/mL) rapidly disproportionates H 2 O 2 to O 2 and H 2 O, and the rate of Cbl(II) oxidation is decreased by the addition of catalase as expected ( Figure S2 ). The addition of 2000 U/mL catalase did not cause any further decrease in the oxidation rate. All kinetic experiments were therefore carried out in the presence of 1000 U/mL catalase. H 2 O 2 also reacts with H 2 OCbl + /HOCbl, albeit at a much slower rate, 12 and the addition of up to 5 mol equiv of H 2 O 2 to H 2 OCbl + /HOCbl does not induce any change in the UV-vis spectrum in the experimental time frame (∆Abs 351 nm < 0.001); hence this reaction is unimportant.
The second-order rate constant for oxidation of Cbl(II) to H 2 OCbl + / HOCbl by O 2
•-was determined by measuring the reaction rate in the presence of varying concentrations of a competitor, Cu,Zn-SOD. (A Mn III SOD mimetic and ferricytochrome c were also tested as possible competitors but found to be unsuitable (see SI)). The initial rate of oxidation of Cbl(II) by O 2
•-was inhibited by Cu,Zn-SOD in a concentration-dependent fashion (Figure 2A ). The rate constant for the reaction between Cbl(II) and O 2
•-was calculated using eq 1 (see SI for derivation), assuming a steady state concentration of O 2 . This indirect competition kinetic method is widely used and well validated. 13 The scatter of the rate (∆Abs/min) data was similar for all experiments (∼0.01 min •-flux (1000 U/mL catalase, phosphate buffer, 25.0°C). Figure S4 ). The smaller ∆Αbs at 474 nm results in a less reliable value of k Cbl . Importantly, since XO requires oxygen for its activity, the experiments were conducted in an aerobic buffer. However, Cbl(II) undergoes slow disproportionation to cob(I)alamin (Cbl(I)) and Cbl(III) () H 2 OCbl + /HOCbl) in air, followed by rapid oxidation of Cbl(I) to Cbl(III). 15 The rate of Cbl(II) autoxidation in the absence of XO was therefore determined and subtracted from the V 0 and V SOD data (dotted line in Figure 2A There is considerable interest in compounds that efficiently scavenge O 2
•-, given their effectiveness in ameliorating conditions associated with oxidative stress.
2b To our knowledge, only one known SOD mimetic, M40401, 2b reacts faster with O 2 •-than Cbl(II) ( Table S1 ). Cbl has an advantage of being nontoxic even at high doses. 17a In our in vitro studies, Cbl(II) is a stoichiometric scavenger of O 2
•-. However, cells also have the ability to re-reduce cob(III)alamins (including H 2 OCbl + /HOCbl) to Cbl(II), 17b making the reaction catalytic. It was of interest to assess the ability of the common vitamin B 12 form in vitamin pills, cyanocobalamin (CNCbl), to prevent elevated intracellular O 2
•-levels in a cell model. We therefore tested the effect of pretreating human aortic endothelial cells (HAEC) with CNCbl prior to exposure to paraquat, a well established O 2
•-source. 18 A 2-fold increase in O 2
•-levels was observed upon exposing HAEC to paraquat (1.5 mM), measured by hydroxylethidium fluorescence (Figure 3) . Preincubating the cells in a medium containing CNCbl (100 nM, 24 h) and subsequently washing the cells to remove extracellular Cbl prior to paraquat exposure resulted in intracellular O 2
•-levels returning to normal. The same effect was observed with SOD itself (Figure 3) . Further details are given in the SI.
To summarize, we have shown that cob(II)alamin, an important intracellular Cbl form, reacts rapidly with O 2
•-at rates approaching those of SOD (7 × 10 8 versus 2 × 10 9 M -1 s -1
, respectively). This suggests that direct scavenging of O 2
•-is an important molecular mechanism by which Cbl modulates intracellular signal transduction and protects against chronic inflammation. Cbl likely acts as a second line of defense when O 2
•-levels overwhelm the SOD protection system, perhaps accounting for the significantly increased oxidative damage markers in patients with inherited disorders of intracellular Cbl metabolism. 19 Given that B 12 is nontoxic even at high doses and that a significant proportion of the elderly are B 12 deficient, our results provide a compelling argument for clinical trials studying the pharmacological effects of B 12 in the treatment and prevention of diseases associated with chronic inflammation and aging. 
